62 filings
Page 2 of 4
8-K
o78p1 upx47yo
14 Jun 23
Regulation FD Disclosure
8:53am
8-K
mb3pr
12 May 23
Regulation FD Disclosure
5:17pm
8-K
j21c81f
28 Apr 23
SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications
9:04am
8-K
c1jlq h6wce97ry
19 Apr 23
SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy
5:05pm
8-K
se6nt pgfeuefdw
14 Apr 23
Regulation FD Disclosure
8:58am
8-K
imrvw80c
4 Apr 23
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
9:34am
8-K
ky3sxy0biqd8six
31 Mar 23
SAB Biotherapeutics Provides Company Update for Full Year 2022
5:12pm
8-K
l0l75twu9p
24 Mar 23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
5:19pm
8-K
i2nqo7a
7 Feb 23
Regulation FD Disclosure
9:03am
8-K
bxol ok6rp
27 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
8-K
mj35bs2ybemcv9
10 Jan 23
Regulation FD Disclosure
9:00am
8-K
fgmvf95lquj le
9 Jan 23
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
9:01am
8-K
9vh7pqcuzal
5 Jan 23
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
4:23pm
8-K
q2shqyyvrs
12 Dec 22
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
9:07am
8-K
6jzsz robu8twcb7
21 Nov 22
Regulation FD Disclosure
4:46pm
8-K
xeuhqjg798bs ml4
7 Nov 22
Regulation FD Disclosure
9:30am
8-K
v8js6le2nt
1 Nov 22
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership
5:06pm
8-K
h14sbe 4i
13 Oct 22
Entry into a Material Definitive Agreement
5:17pm
8-K
nw85bm a2w01irf5
7 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:09pm
8-K
5b6rssp2
30 Sep 22
Regulation FD Disclosure
9:12am